ClinicalTrials.gg
RecruitingNCT05618041Updated Jun 24, 2025

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

An interventional study of CAR-T Autologous T cell injection in Acute Lymphoblastic Leukemia, Lymphoma and Multiple Myeloma, sponsored by Hebei Senlang Biotechnology Inc., Ltd.. Recruiting at 1 site in China. Open to participants aged 14 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by Hebei Senlang Biotechnology Inc., Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
14 Years to 75 Years
Sex
All
01

Study summary

To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.

Read the detailed description

Main research purposes:

To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.

Secondary research purposes:

Objective Evaluation of Cytodynamic Characteristics of CAR-T in Different Types of Hematological Malignancies

02

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Lymphoma
  • Multiple Myeloma

Keywords

  • CD19,CD20,BCMA
  • B-ALL/MM/NHL
03

In context

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,584 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.

This study's planned enrollment of 50 is above the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Lead sponsor

Hebei Senlang Biotechnology Inc., Ltd. is the lead sponsor of 40 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the and be willing and able to comply with the visit, treatment protocol, laboratory examination, and other requirements of the study as specified in the study procedure sheet;
  • Diagnosed as recurrent or lymphoma, leukemia or myeloma;
  • Tumor cells express targets for CAR-T cell therapy (results: flow cytometry or Immunohistochemical test confirmation);
  • Age 14-75 (including threshold), gender unlimited;
  • (ECOG) score ≤2;
  • HGB ≥ 70g/L (blood transfusion allowed);
  • Liver and kidney functions, heart and lung functions meet the following requirements:

    1. Creatinine ≤ 1.5 × ;
    2. ≥ 50%;
    3. Blood oxygen saturation>90%;
    4. Total ≤ 1.5 × ULN; and AST ≤ 2.5 × ULN;
  • For T cell tumor patients, if tumor cells are detected in peripheral blood during screening, flow cytometry should be used to detect that the tumor cell surface immunophenotype is CD4 and CD8 double negative. If the immunophenotype of peripheral blood tumor cells is not double negative for CD4 and CD8, the condition that the proportion of peripheral blood tumor cells is ≤ 1% shall be met;
  • Subjects with pregnancy plans must agree to use before entering the study and after the study lasts for six months; If the subject is pregnant or suspected of being pregnant, the investigator shall be informed immediately;
  • The subject or guardian understands and signs the informed consent form;
  • Expected survival longer than 3 months.

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac insufficiency;
  • Have a history of severe lung impairment;
  • Complicated with other advanced malignant tumors;
  • Complicated with severe or persistent infection that cannot be effectively controlled;
  • Complicated with severe diseases or congenital immune deficiency;
  • Active hepatitis ( or positive);
  • (HIV) infection or syphilis infection;
  • Have a history of severe allergy to biological products (including antibiotics);
  • If there is a history of hematopoietic stem cell transplantation, it should be no more than 6 months before the patient receives hematopoietic stem cell transplantation;
  • Subjects who received CAR-T therapy or other gene modified cell therapy before screening;
  • Conditions that the investigator believes may increase the risk to the subject or interfere with the outcome of the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    CAR-T Autologous T cell injection

    Patients will be treated with CAR-T cells

    Biological: CAR-T Autologous T cell injection

Interventions

  • BiologicalCAR-T Autologous T cell injection

    Biological: CAR-T; Drug: Cyclophosphamide,Fludarabine;Procedure: Leukapheresis

    Also known as: CD19 CAR-T, CD20 CAR-T, BCMA CAR-T

06

What researchers measure

Primary outcomes

  1. Safety: Incidence and severity of adverse events

    To evaluate the possible adverse events occurred within first one month after CAR-T infusion, including the incidence and severity of symptoms such as cytokine release syndrome and neurotoxicity

    Time frame: First 1 month post CAR-T cells infusion

  2. Efficacy: Remission Rate

    Complete remission (CR) Complete remission with incomplete recovery of blood cells (CRI), positive minimal residual tumor (MRD+) or negative tumor (MRD -) CR/CRI, disease recurrence or progression (PD) were evaluated, and the overall remission rate was ORR=CR+CRI; For drenching Complete remission (CR), partial remission (PR), disease stability (SD) Disease recurrence or progression (PD) was evaluated, and the overall remission rate was ORR=CR+PR; For multiple myeloma Complete remission (CR), partial remission (VGPR, PR), disease stability (SD), disease recurrence or progression (PD) were adopted, Overall remission rate ORR=CR+VGPR+PR;

    Time frame: 3 months post CAR-T cells infusion

Secondary outcomes

  1. progression-free survival (PFS)

    progression-free survival (PFS) time

    Time frame: 24 months post CAR-T cells infusion

  2. CAR-T proliferation

    the copy number of Senl CAR- T cells in the genomes of PBMC by qPCR method

    Time frame: 3 months post CAR-T cells infusion

  3. Cytokine release

    Cytokine( IL-6,IL-10,IFN-γ,TNF-α ) concentration (pg/mL) by flow cytometry method

    Time frame: 1 month post CAR-T cells infusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • He S, Peng J, Yang X, Meng F, Huang L, Huang L, Tian W, Gao Z, Zhao J, Wang Z, Wei J. Peripheral Blood Smears Distinguish Infective Fever after CAR-T Therapy. Front Biosci (Landmark Ed). 2023 Nov 24;28(11):299. doi: 10.31083/j.fbl2811299. PubMed 38062808 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05618041
Collaborators
Hebei Taihe Chunyu Biotechnology Co., Ltd
Responsible party
Sponsor
First posted
Nov 16, 2022
Start date
Sep 7, 2022
Primary completion
Sep 6, 2027 (estimated)
Completion
Dec 6, 2027 (estimated)
Last update
Jun 24, 2025

Study contacts

Weiwei w Tian, MD
Contact
tianweiwei@yeah.net
008613485304136
Na Kuang, MD
Contact
kuangna@senlangbio.com
008618630160116
Weiwei w Tian, MD
study director · Shanxi Bethune Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion